Sanofi: Obesity trials
The registry lists 21 Obesity studies with Sanofi as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 2 3Phase 3 18(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese PatientsTerminatedNCT00678483Phase 3
- Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese PatientsCompletedNCT00481975Phase 3
- Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese PatientsCompletedNCT00481923Phase 3
- Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and ExerciseTerminatedNCT00478972Phase 3
- Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic DrugTerminatedNCT00478595Phase 3
- Japanese Dose-Response Study of Rimonabant in Obese PatientsCompletedNCT00459004Phase 2
- Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk FactorsTerminatedNCT00458081Phase 3
- Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)TerminatedNCT00434096Phase 3
- European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemiaTerminatedNCT00412698Phase 3
- High Density Lipoprotein TurnoverTerminatedNCT00408148Phase 3
- Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood GlucoseTerminatedNCT00405808Phase 3
- Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)CompletedNCT00386061Phase 3
- Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic DyslipidemiaCompletedNCT00345410Phase 2
- Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)CompletedNCT00325546Phase 3
- Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and OutcomesTerminatedNCT00263042Phase 3
- An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese PatientsCompletedNCT00239967Phase 3
- A Multicenter Study to Evaluate the Efficacy and Safety of of Four Doses of SR147778 in Obese PatientsCompletedNCT00239174Phase 2
- Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on RimonabantTerminatedNCT00228176Phase 3
- Obese Patients With or Without Comorbidities (RIO-North America)CompletedNCT00029861Phase 3
- Obese Patients With Type 2 DiabetesCompletedNCT00029848Phase 3
- Obese Patients With Untreated DyslipidemiasCompletedNCT00029835Phase 3